Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest
Authors:
- David H. BirnieDBDavid H. Birnie
- Christie SambellCSChristie Sambell
- Helen JohansenHJHelen Johansen
- Kathryn WilliamsKWKathryn Williams
- Robert LemeryRLRobert Lemery
- Martin S. GreenMGMartin S. Green
- Michael H. GollobMGMichael H. Gollob
- Douglas S. LeeDLDouglas S. Lee
- Anthony S.L. TangATAnthony S.L. Tang
- 3 July 2007
- journal article
- research article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 177 (1) , 41-46
Abstract
Background: Cardiac arrest due to ventricular arrhythmia in the absence of a reversible cause or contraindication has been a class I indication for insertion of an implantable cardioverter defibrillator since 1998. We compared and contrasted the use of implantable cardioverter defibrillator therapy in Canada and the United States among adults who survived a cardiac arrest. Method: Data on hospital separations from April 1, 1994 through March 31, 2003 were obtained from the Health Person-Oriented Information Database maintained by Statistics Canada and from the US National Hospital Discharge Survey on all patients with a primary diagnosis of cardiac arrest, ventricular fibrillation or ventricular flutter for the same 9-year period. We excluded all records of patients with a secondary diagnosis of acute myocardial infarction. Results: In Canada, 3793 patients survived to discharge after a cardiac arrest; 628 (16.6%) of these were implanted with a cardioverter defibrillator before discharge. The implant rate rose steadily from 5.4% in 1994/95 to 26.7% in 2002/03. In the United States, 23 688 (30.2%) of 78 538 such survivors received an implantable cardioverter defibrillator before discharge. Logistic regression analysis indicated that sex, age, fiscal year, the hospital9s teaching status, hospital size and patient history of heart failure were positive predictors of implantable cardioverter defibrillator implantation. Age, renal failure, liver failure and cancer were negative predictors of receiving an implantable cardioverter defibrillator. Interpretation: The rate of use of implantable cardioverter defibrillator therapy for cardiac arrest survivors in Canada is increasing, but still is lower than the rate in the United States.Keywords
This publication has 32 references indexed in Scilit:
- Influence of gender on ICD implantation for primary and secondary prevention of sudden cardiac deathEP Europace, 2006
- Gender Differences in the Management and Clinical Outcome of Stable AnginaCirculation, 2006
- Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002New England Journal of Medicine, 2005
- Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up studyCanadian Medical Association Journal, 2004
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Utilization of implantable cardioverter-defibrillators in survivors of cardiac arrest in the United States from 1996 to 2001JACC, 2004
- Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular TachyarrhythmiasCirculation, 2002
- Meta-analysis of the implantable cardioverter defibrillator secondary prevention trialsEuropean Heart Journal, 2000
- Bias in the Coding of Hospital Discharge Data and Its Implications for Quality AssessmentMedical Care, 1994
- Accuracy of Diagnostic Coding for Medicare Patients under the Prospective-Payment SystemNew England Journal of Medicine, 1988